The stock price of Cirio, a small Norwegian biotech company, has surged more than 1250 percent since early June. On June 3, the shares traded at 0.45 Norwegian kroner. By August 1, they reached 6.10 kroner. This rapid increase has drawn attention from investors and analysts alike.
CEO Ole Kristian Stemland called the rise extraordinary. In a statement on July 29, he noted the company's progress in clinical trials for its lead drug candidate. Stemland said the results exceeded expectations, driving investor confidence. The company plans to submit final trial data to regulators by October.
Analysts at DNB Markets described the surge as unsustainable in the short term. Senior equity analyst Kristian Solheim warned of potential volatility. He pointed to the small float of shares, which makes the stock sensitive to large trades. Solheim added that without further news, the price could correct sharply.
The surge has made Cirio one of the best-performing stocks on the Oslo Stock Exchange this year. Its market capitalization now exceeds 1.2 billion kroner, up from 40 million in April. The company employs 25 people and focuses on treatments for rare diseases.
Investors holding shares since April have seen massive gains. However, those buying at the peak face significant risk. The company has not yet generated revenue and relies on external funding for operations.
Source: e24.no